EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY 4.0

Cannabidiol (CBD): A Systematic Review of Clinical and Preclinical Evidence in the Treatment of Pain

Guillermo Cásedas iD, Martín de Yarza-Sancho, Víctor López iD

Pharmaceuticals · 28.10.2024 · 17 (11) · 1438

DOI: 10.3390/ph17111438 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 28.10.2024. Verfasst von Guillermo Cásedas und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Faculty of Health Sciences, Universidad San Jorge, 50830 Zaragoza, Spain. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad San Jorge, Gobierno de Aragón.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Cannabis sativa L. is a plant that has been used for thousands of years for its industrial and medicinal properties. In recent years, there has been a rise in the study of this plant due to its bioactive compounds for pharmaceutical applications. Particularly, cannabidiol has demonstrated analgesic and non-psychoactive properties. The objective of this systematic review is to update and to gather the clinical and preclinical evidence on CBD in pain treatment.

Methods

This study was performed following the PRISMA guidelines and using the following search terms “((cannabidiol) NOT (THC)) NOT (tetrahydrocannabinol)) AND (pain treatment)” in PubMed and Web of Science, with the following inclusion criteria: CBD pain treatment without THC in monotherapy, including both clinical and preclinical trials. From the initial sample of more than 500 articles, a total of 40 studies were selected, eliminating duplicate studies from the databases and considering the inclusion and exclusion criteria. On one hand, clinical trials were analyzed using CBD products without THC used in monotherapy, assigning a Jadad score to evaluate the quality/bias of the trials; on the other hand, the main preclinical trials were analyzed, grouping the results into in vivo and in vitro trials.

Results

Based on the review conducted, there is sufficient clinical and preclinical evidence of CBD in pain treatment, so CBD could be an effective and safe treatment in reducing pain due to its analgesic and anti-inflammatory properties. These effects appear to be primarily mediated by the activation of TRPV-1, 5HT-1A, and CB1, with emerging therapeutic relevance in the management of osteoarthritis and chronic pain.

Conclusions

Although clinical and preclinical research show promising results, clinical evidence is limited, and more studies should be performed in the future with isolated CBD.

Schlagwörter

Stichwörter der Autor:innen

CBDanalgesiccannabinoidscannabisclinical trialspain

Autor:innen und Institutionen

  • Department of Pharmacy, Faculty of Health Sciences, Universidad San Jorge, 50830 Zaragoza, Spain.
  • Instituto Agroalimentario de Aragón-IA2, CITA-Universidad de Zaragoza, 50009 Zaragoza, Spain.

ORCID-Profile: Guillermo Cásedas, Víctor López

Förderung

  • Universidad San Jorge
  • Gobierno de Aragón

Zitieren

APA

Cásedas, G., Yarza-Sancho, M., & López, V. (2024). Cannabidiol (CBD): A Systematic Review of Clinical and Preclinical Evidence in the Treatment of Pain. Pharmaceuticals, 17(11), 1438. https://doi.org/10.3390/ph17111438

Vancouver

Cásedas G, Yarza-Sancho M, López V. Cannabidiol (CBD): A Systematic Review of Clinical and Preclinical Evidence in the Treatment of Pain. Pharmaceuticals. 2024;17(11):1438. doi:10.3390/ph17111438

BibTeX
@article{Csedas2024,
  author = {Cásedas, Guillermo and Yarza-Sancho, Martín de and López, Víctor},
  title = {Cannabidiol (CBD): A Systematic Review of Clinical and Preclinical Evidence in the Treatment of Pain},
  journal = {Pharmaceuticals},
  year = {2024},
  volume = {17},
  number = {11},
  pages = {1438},
  doi = {10.3390/ph17111438}
}
Kostenlos starten →